◼ Archived
Health
🔮 fades ✓
Scientists Say a Key Trigger for Alzheimer’s Damage Isn’t Even in the Brain
A bone‑marrow immune pathway may be the missing link behind Alzheimer’s brain damage.
Tau Protein
7 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Tau Protein
This hub groups 7 separate news trends connected to Tau Protein, spanning July 14, 2026 through September 7, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 49 article observations and 48 source signals, led by Health, Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Health
🔮 fades ✓
Scientists Say a Key Trigger for Alzheimer’s Damage Isn’t Even in the Brain
8 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
An Alzheimer’s Drug Cut Expected Cognitive Decline Roughly in Half. It Didn’t Target Amyloid
New clinical data on the drug diranersen shows a reduction in cognitive decline, shifting the Alzheimer’s treatment discourse away from amyloid-only targets.
◼ Archived
Health
🔮 fades ✓
Study reveals new role for tau, a top target for Alzheimer’s drug development
New research on tau protein may transform Alzheimer’s treatment and diagnosis
◼ Archived
Health
🔮 fades ✓
Scientists discover a protein that protects the brain from Alzheimer’s damage
Scientists have identified the SORLA protein as a potential defense mechanism against Alzheimer's disease and toxic tau tangles.
◼ Archived
Health
🔮 fades ✓
Rare Autopsy Finds Alzheimer's Drugs Only Work in Some Parts of The Brain
New clinicopathologic research indicates that Alzheimer's drugs targeting amyloid plaques exhibit varying efficacy across different regions of the brain.
◼ Archived
Business
🔮 fades ✗
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen’s experimental tau-targeting Alzheimer’s drug sparks industry debate following mixed clinical trial results.